|Publication number||USRE43389 E1|
|Application number||US 11/506,164|
|Publication date||May 15, 2012|
|Filing date||Aug 12, 1999|
|Priority date||Aug 12, 1998|
|Also published as||CA2348152A1, CA2348152C, CN1196796C, CN1321200A, DE19836559A1, DE59914991D1, EP1105533A1, EP1105533B1, EP2071037A1, EP2206792A1, US6776959, US20130066234, WO2000009746A1|
|Publication number||11506164, 506164, PCT/1999/5857, PCT/EP/1999/005857, PCT/EP/1999/05857, PCT/EP/99/005857, PCT/EP/99/05857, PCT/EP1999/005857, PCT/EP1999/05857, PCT/EP1999005857, PCT/EP199905857, PCT/EP99/005857, PCT/EP99/05857, PCT/EP99005857, PCT/EP9905857, US RE43389 E1, US RE43389E1, US-E1-RE43389, USRE43389 E1, USRE43389E1|
|Original Assignee||Preanalytix Gmbh|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (99), Non-Patent Citations (41), Referenced by (2), Classifications (30), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Applicant claims priority under 35 U.S.C. §119 of GERMAN Application No. 198 36 559.4 filed on Aug. 12, 1998. Applicant also claims priority under 35 U.S.C. §120 of PCT/EP99/05857, filed on Aug. 12, 1999. The international application under PCT article 21(2) was not published in English.
The present invention relates to a vessel for withdrawing blood, and the blood withdrawn should especially be used for stabilizing and analyzing nucleic acids.
When blood is taken, it is normally collected in vessels which already contain anticoagulants such as heparin, citrate or EDTA. The blood is thereby prevented from coagulating. The blood samples obtained thereby can be stored at suitable temperatures for a long time. This way of obtaining blood has, however, considerable drawbacks when nucleic acids such as (m)RNA or DNA are to be analyzed. For such purposes the nucleic acids contained in the sample should optimally be stabilized already at the moment of withdrawal, i.e. a degradation of the existing nucleic acids should be prevented, but also the new synthesis of mRNA.
This objective of a stable storage of the nucleic acids contained in the sample material, i.e. from the moment of withdrawal, has not been achieved yet in practice for the following reasons:
Cells contain nucleases, enzymes, which destroy nucleic acids as soon as they come into contact with the substrates thereof (RNA, DNA). The effect of cellular and extracellular nucleases is normally under physiological control as long as the cells are in their normal environment. The withdrawal of blood effects more or less strong changes in the nucleic acids contained in the cells. Nucleases are then released within the cells and/or by the lysis of cells to the outside. Moreover, nucleic acids are synthetized more or less strongly. In particular the long-term storage of blood leads to aging and destruction of the cells.
Another problem arising in the long-term storage of blood samples obtained according to standard withdrawal methods is the considerable change in the sample material. Such changes, e.g. strong lysis of cells, may have the effect that the standard methods for isolating nucleic acids no longer function in an adequately efficient way.
Apart from the problems regarding a stable storage of nucleic acids contained in the sample material, further difficulties arise in the conventional method for withdrawing blood. The conventional anticoagulants are often not separated efficiently enough during isolation of nucleic acids and interfere with in the subsequent analysis of nucleic acids, e.g. in the case of amplification by means of PCR (polymerase chain reaction). Heparin is e.g. a generally known inhibitor of PCR.
Finally, the question arises in the quantitative analysis of nucleic acids how the whole method ranging from sampling to the measurement of nucleic acids can be controlled under standardized conditions. Ideally, a quantitatively and qualitatively defined standard nucleic acid should already be added to the sample material during withdrawal and should be subjected to the whole process of sampling and determination. This can also not be accomplished with the conventional withdrawal systems.
A further drawback of conventional blood withdrawal is the risk of transferring infectious material because manual process steps have so far been needed for the isolation of nucleic acids. Contact with potentially infectious germs cannot be ruled out.
In the literature there is described a method in which the blood sample is mixed with guanidinium salt directly after withdrawal from a patient (EP 0 818 542 A1). In this method the guanidinium salt is present in powder form to thereby exploit the increased stability of the guanidinium salt. This method, however, has serious drawbacks because the salt, for instance, must first dissolve in the added blood. This dissolution process depends, in particular, on the temperature and cannot be controlled because of the nontransparent sample material used. The use of a corresponding product for diagnostic medical purposes is thus very problematic.
Furthermore, nucleases are extremely active enzymes which can only be inhibited under extremely denaturing conditions. Denaturation depends on the concentration of the guanidinium salt in solution. An inhibiting concentration of guanidinium salt in solution does not exist in the cited method right from the beginning. Thus, there is an uncontrolled degradation of nucleic acids during the dissolution process. Moreover, in this method the addition of reducing agents is omitted, without which an efficient inhibition, in particular of RNases, is not ensured (see Example no. 5).
Moreover, the sample prepared in this way cannot directly be used for the further nucleic acid isolation on glass surfaces. Moreover, the use of guanidinium salt powder does not permit the addition of internal nucleic acid standards. Such standards are mandatory for process control and exact quantification.
The present invention has been based on the technical problem of providing a vessel for withdrawing blood which does not have the drawbacks of the prior art. In particular, it should be possible to subject the sample taken with the vessel directly to the standard methods for analyzing nucleic acids without the need for further sample preparation steps.
According to the invention this problem is solved by a vessel for withdrawing blood, the vessel containing an aqueous solution comprising the following components:
The vessel of the invention has the following advantages: 1. Blood is already lysed at the moment of withdrawal in that the withdrawal vessel already contains a nucleic acid-stabilizing substance in solution. 2. The nucleic acid-stabilizing substance is composed such that the sample material, in particular the nucleic acids contained therein, are directly stabilized upon contact with the solution. 3. In contrast to all of the former standard withdrawal systems, such as EDTA or heparin-containing withdrawal vessels, the stabilized sample need no longer be handled as infectious material. 4. The nucleic acid-stabilizing substance is composed such that the sample material can directly be used in subsequent isolating methods. 5. The nucleic acid-stabilizing substance can be separated during subsequent isolation so efficiently that an inhibition of PCR is not observed. 6. The nucleic acid-stabilizing substance may have added thereto an internal standard. This permits the control of the whole method from the moment of sampling up to the detection of nucleic acids.
The withdrawal vessel mentioned under item 1 is a conventional blood withdrawing vessel (small tube) which has introduced thereinto a defined volume of a nucleic acid-stabilizing substance. The small tube is then preferably subjected to a defined vacuum which guarantees that only a specific volume of blood can flow thereinto during withdrawal. The small tube can be handled by conventional blood-taking methods. The solution contained in the tube contains the following reagents in a specially preferred embodiment: Guanidinium thiocyanate, Triton-X-100, dithiothreitol and a suitable buffer system, such as citrate, Tris or HEPES. In the described composition the solution is compatible with the vacuum tube. This solution can be stored in the vacuum tube without any problems and without any impairment of the desired stabilizing function. The whole system presents no problems, in particular to blood donors, and is safe during sampling.
The solution containing the guanidinium salt, the buffer substance, the reducing agent and/or the detergent is stable in storage and converts the supplied and freshly taken blood into a material which is also stable in storage and can directly be subjected to the standard nucleic-acid analysis kits (e.g. those of Roche or Qiagen).
Guanidinium thiocyanate and/or guanidinium chloride are preferred as guanidinium salt.
Preferably, the guanidinium salt is present in a concentration of 2.0 to 8.0 M. Tris or citrate is preferred as the buffer substance, the exact pH being preferably adjusted with HCl. Further possible buffers are however HEPES, MOPS, citrate and phosphate buffer, such as PBS.
The buffer concentration is preferably between 10 and 300 mM, particularly preferably between 10 and 100 mM.
Triton-X-100 is preferred as the detergent. Further possible detergents are NP40, Tween 20, polydocanol or other detergents.
The detergent concentration is preferably at 5 to 30% (w/v), particularly preferably at 10 to 20% (w/v).
DTT is preferred as the reducing agent, but β-mercaptoethanol, TCEP (Tris(2-carboxyethyl)phosphine) or other reducing agents can also be used.
The preferred concentration of the reducing agent is at 0.1 to 10% (w/v), particularly preferred are 0.5 to 2% (w/v).
The pH of the solution is preferably at 3.0 to 9.0, particularly preferably at 4.0 to 7.5, particularly preferably at 5 to 6.
The pH of the solution is in particular chosen such that a pH ranging from 5.0 to 7.6 is set after addition of the sample material. Particularly preferred is a pH between 6.3 and 6.9 (see Example no. 8).
A particularly preferred solution preferably contains 4 M guanidinium thiocyanate, 45 mM Tris/HCl, 18%, preferably 15% (w/v) Triton-X-100, 0.8% (w/v) DTT and has a pH of 6.0.
In a further preferred embodiment the volume for receiving the blood sample has a negative pressure which can be adjusted such that a previously determined blood volume is sucked into the vessel after a blood vessel has been pierced. Correspondingly evacuated vessels are available on the market.
The vessel which contains the blood taken can then immediately be subjected to further analyses or, however, may be stored for a long period of time (up to several days) without any disadvantages for the quality of the sample.
In the method of the invention the freshly taken blood is directly contacted in the blood withdrawing vessel with the above-described solution so that all processes which might change the nucleic acid pattern of the sample are immediately stopped. Therefore, the data determined at a later time with respect to the detected nucleic acids very accurately represent the actual state at the time of blood withdrawal, i.e. both with respect to the quantities and the types of nucleic acids.
Preferably, the blood amount taken is 0.1 to 4 times the solution fed into the vessel. The solution is preferably 0.5 to 5.0 ml. Thus the final concentration of guanidinium salt after blood addition is at 1.0 to 5 M, preferably at 1 to 3 M, particularly preferred are 2-3 M (see Example 7).
The vessel according to the invention is preferably used for blood withdrawal when the blood sample is to be used for analyzing nucleic acids. The use of the above-mentioned solution as a component of the described withdrawal system solely guarantees the immediate lysis of the cells and the simultaneous stabilization of the sample by immediate inactivation of the nucleases. Surprisingly, the blood sample obtained thereby can be stored even at room temperature or higher for several days. Moreover, the withdrawal system guarantees a contamination-free and non-infectious handling ranging from sampling via nucleic acid isolation to analysis. In the conventional methods of nucleic acid isolation, additional handling steps have so far been required (e.g. the transfer of the blood sample taken into the reagents for nucleic acid isolation, etc.), which entails an additional risk of infection.
The sample obtained with the blood withdrawing system is compatible with all of the conventional standard methods of nucleic acid isolation. Particular attention should here be paid to methods which are based on the binding of nucleic acids to glass surfaces, but also sequence-specific binding to complementary nucleic acid and solvent-based extraction methods.
Thus the invention as described consists of a blood withdrawing system which is conceived such that the following conditions are satisfied. 1. Controlled sampling and simultaneous stabilization of the nucleic acids (DNA, RNA) contained in the sample material. 2. Sampling in which the use of anticoagulants can be completely omitted. 3. The sample obtained by way of the above-described blood withdrawing system can be used in a universal manner in all of the known systems for isolating nucleic acids. 4. The blood withdrawing system is stable in storage.
Additionally, it has surprisingly been found that the sample obtained by way of the described withdrawal system can be stored in the vessel for a long period of time without degradation of the nucleic acids (see Examples 2, 3, 7, 8).
The following examples will explain the invention:
The blood withdrawing system may be composed in a preferred embodiment as follows (see
General preliminary remark regarding the following examples.
In all of the examples described hereinbelow, the nucleic acid-stabilizing substance (N-sS) had, unless indicated otherwise, the following composition: 45 mM Tris, 5 M guanidinium thiocyanate (GTC), 0.8% (w/v) dithiothreitol (DTT), 18% (w/v) Triton-X-100, pH 6.0.
In all of the examples described, the nucleic acid-stabilizing substance was, unless indicated otherwise, mixed with the sample in the ratio of 1 to 1 (1 volume N-sS plus 1 volume sample material). A lower concentration of N-sS, e.g. 1 volume N-sS plus 5 volumes sample, might effect a degradation of RNA.
Blood was stabilized for all examples by directly feeding the blood upon withdrawal into the small tube mixed with N-sS.
Stability of nucleic acid after mixture of sample material and N-sS. Isolation of RNA and DNA from the sample lysate with silica-derivatized surfaces.
Material and Method
The sample material for the DNA and RNA isolation was directly used after withdrawal, after storage at 4° C. for 6 days, and after storage at −20° C. for 1 month.
The High Pure RNA Isolation Kit (Boehringer Mannheim, cat. no. 1828 665) was used for isolating RNA (
For the isolation of DNA (
Isolation of mRNA from sample lysate using streptavidin-coated magnetic particles and biotin-labeled Oligo(dT) (
Material and Method
20 ml sample lysate was fed into a vessel. The mRNA was isolated according to the following method: First of all 30 ml hybridization buffer (20 mM Tris-HCl, 300 mM NaCl, 6 nM biotin-labeled Oligo(dT), pH 7.4) was added to the lysate. 3 mg streptavidin magnetic particles (Boehringer Mannheim) were then added. The sample was mixed and incubated at room temperature for 5 min. The magnetic particles were separated with the help of a magnet; the supernatant was discarded. The particles were then resuspended in wash buffer 1 (10 mM Tris-HCl, 200 mM NaCl, 1% Triton-X-100, pH 7.5) and washed three times with wash buffer 2 (10 mM Tris-HCl, 200 mM NaCl, pH 7.5) (wash steps: resuspension, magnetic separation, removal of the supernatant). After the last wash step the supernatant was completely removed and the particles were resuspended in 20 μl distilled water. The sample was heated to 70° C. for 5 min. The magnetic particles were separated, and the supernatant which contained the mRNA was analyzed by means of gel electrophoresis.
Isolation of DNA and RNA using a modified rule according to Chomczynski and Sacchi (Analytical Biochemistry 162, 156-159 (1987)) (example of a method based on solvent extraction) (
Material and Method
2 ml sample volume was transferred from the blood withdrawing vessel into a small tube. 0.2 ml of a 2 M sodium acetate solution, pH 4, 2 ml phenol (water saturated) and 0.4 ml of a chloroform-isoamyl alcohol mixture (49:1) were then added, the sample being thoroughly mixed after addition of each solution. The complete solution was vigorously shaken for 10 seconds and incubated on ice for 15 minutes. The sample was centrifuged for 20 minutes at 4° C. at 10000 g. After centrifugation the RNA was in the aqueous phase; the DNA and proteins in the intermediate and phenol phase. The aqueous phase was transferred into a new vessel and mixed with 1 ml isopropanol. For precipitating the RNA the sample was stored at −20 C. for 1 hour. After renewed centrifugation at 4° C. at 10000 g the RNA was pelleted. The pellet was resuspended in 0.3 ml buffer (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1 M 2-mercaptoisopropanol), transferred into a new 1.5 ml Eppendorf vessel and mixed with 1 volume of isopropanol. After incubation at −20° C. for 1 hour the solution was centrifuged in an Eppendorf centrifuge at 4° C. for 10 minutes. The RNA pellet was received in 75% ethanol and concentrated by centrifugation (Speed vac) and dried. For further processing the sample was dissolved in 100 μl 10 mM Tris-HCl, pH 6.5.
Importance of reducing reagents (such as DTT) in the stabilizing solution for the longterm stability of RNA
Material and Method
Stabilizing solution used: 4.0 M GTC; 13.5% Triton X100; 45 mM Tris//HCl; with or without 120 mM DTT. 700 μl serum was mixed with 700 μl stabilizing solution. After incubation for 2 min 20 μl MS2-RNA (0.8 μg/μl of Roche) was added. The samples were incubated at 40° C. for 180 min and then processed in aliquots of 400 μl each with the High Pure total RNA Kit of Roche. The samples were applied in one step to the column without addition of the binding reagent of the kit and centrifuged in accordance with the instructions. The following wash steps and the elution of the RNA in 50 μl elution buffer were carried out in accordance with the instructions.
The analysis was carried out by means of agarose gel (see
Stability of Free MS2-RNA in Serum. Kinetics of the RNA Degradation by Sample Components
Material and Method
250 μl serum was spiked with 10 μl MS2-RNA (0.8 μg/μl of Roche) and incubated at room temperature. Immediately after the addition of RNA, after 2 min to 50 min, the natural RNA degradation in serum was stopped by adding 250 μl stabilizing solution. All batches were analyzed twice. As a standard, a sample was only mixed with MS2-RNA after addition of the stabilizing solution to the serum and was processed in parallel.
All samples were processed in parallel with the High Pure viral RNA Kit of Roche. The samples were applied to the column in one step without addition of the binding reagent of the kit and centrifuged according to instructions. The following wash steps and the elution of RNA in 50 μl elution buffer were carried out according to instructions. 20 μl of the eluate was separated by means of a 1.2% native agarose gel and analyzed (see
Result: MS2-RNA is not stable in serum. Already 2 minutes after addition of RNA to the serum the RNA is completely degraded. By the addition of stabilizing solution to the serum in the ratio of 1:1, this process can be stopped immediately, and a stabilization of the RNA can be achieved at the time when the stabilizing solution is added (=blood withdrawal).
Stability of MS2-RNA in Serum/stabilization Solution. Dependence on the GTC Concentration
Material and Method
Stabilization solutions used: 3-5 M GTC; 13.5% Triton X100; 50 mM DTT; 42 mM Tris/HCl
pH of the solutions: about 4.0
pH of the solutions after addition of serum: about 6.7.
2 ml serum was mixed with 2.5 ml of the respective stabilization solutions. After an incubation time of 2 to 5 min 90 μl MS2-RNA (0.8 μg/μl of Roche) was added and incubated at 40° C. 400 μl samples were taken at regular intervals and processed with the High Pure total RNA Kit of Roche according to Example 5. The samples were eluted in 50 μl and frozen at −20° C. For the analysis of the RNA integrity 20 μl of the eluate was applied to a 1.5% agarose gel (see
For the PCR analysis of the samples 10 μl of the eluate was reversely transcribed by means of AMV-RT (Roche) and subsequently analyzed by means of PCR on the Lightcycler:
Batch for RT:
μl AMV-RT buffer
(42° C. for 1 h)
μl dNTP's (final concentration 10 mM)
μl RNase inhibitor (Roche, 20 units)
μl Primer 2827 (final concentration 1 μM)
μl DMPC water
μl AMV-RT (Roche, 15 units)
μl template RNA
The PCR was carried out on the Lightcycler at an annealing temperature of 61° C. using SYBR-Green as detection system. Batch for PCR:
μl MgCl2 (batch solution 25 mM)
μl DMPC water
μl Primer 2827 (batch solution 20 mM)
μl Primer 2335 (batch solution 20 mM)
μl SYBR-Green-Mastermix (Roche)
μl RT batch (1:50 diluted)
The amplificate of the PCR was completely applied to a 2% agarose gel (see
RNA integrity at 40° C. after 3 days.
The agarose gel in
Amplificability of the RNA at 40° C. after 8 days.
Although a beginning degradation of the RNA was already detected at 40° C. after 3 days, all of the RNA samples could be amplified after an incubation of 8 days at 40° C. and clearly detected.
The amplificate of the PCR was fully applied to a 2% agarose gel (see
Stability of MS2-RNA in Serum/stabilization Solution: Dependence on the pH of the Sample Mixed with Stabilization Solution
Material and Method
Solution used: 4M (5M) GTC 14.4% Triton X 100 50 mM DTT 45 mM Tris/HCl
pH after serum addition between 6.7 and 8.0
2.5 ml stabilization solution was mixed with 2.0 ml serum. After addition of 90 μl MS2-RNA (0.8 μg/μl, Roche) the samples were incubated at room temperature. The RNA was processed at regular intervals from 500 μl sample with the Roche viral RNA kit according to Example 6 and isolated in 50 μl elution buffer. 20 μl of the eluate was analyzed by means of agarose gel (see
The pH of the serum/stabilization solution and thus the pH and the buffer range of the stabilization solution are decisive for the long-term stabilization of RNA. While at a pH of 8.0 an intact RNA could no longer be detected already after 2 days, intact RNA is still detectable within a pH range between 6.6 and 7.0 after 13 days of incubation at room temperature.
Apart from the pH, however, an optimally adjusted GTC concentration is also of importance to the long-term stabilization of RNA (see also Example 7). The illustrated example demonstrates that a GTC final concentration in the stabilized sample of 2.2 M GTC is better than 2.78 for a long-term stabilization of RNA.
Sampling vessel with N-sS, defined vacuum, sealed with septum.
Gel analysis (1% agarose) of RNA which was stored in the sampling vessel for different periods of time. Column 1: Isolation directly after sampling (no storage), column 2: storage for one month at −20° C., column 3: storage for 6 days at 4° C. The amount of the applied RNA corresponded to a blood volume of 120 μl.
Gel analysis (1% agarose) of DNA which was stored in the sampling vessel for different periods of time. Column 1: isolation directly after sampling (no storage), column 2: storage for one month at −20° C., column 3: storage for 6 days at 4° C. The amount of the applied DNA corresponded to a blood volume of 10 μl.
Gel analysis (1% agarose) of mRNA which was isolated from 10 ml blood (column 2). Molecular weight marker (column 1). In addition to the mRNA, the rRNA bands are visible. The sharp contours of the bands demonstrate the integrity of the nucleic acids.
Gel analysis (1% agarose) of the RNA which was isolated from 120 μl blood.
Gel analysis of isolated MS2-RNA after incubation in serum/stabilization solution with/without DTT for 180 min at 40° C.
Column 1: positive control: MS2-RNA, column 2: DNA marker, column 3,4,5: MS2-RNA after incubation with DTT-containing stabilization solution, column 6,7,8: MS2-RNA after incubation with stabilization solution without DTT.
Gel analysis of isolated MS2-RNA after incubation in serum for 0-50 min
Column 10,17: MS2-RNA standard, column 9,16: DNA marker, column 7,8: incubation for 0 min, column 5,6: incubation for 2 min, column 3,4: incubation for 5 min, column 1,2: incubation for 10 min, column 11,12: incubation for 15 min, column 13,14: incubation for 30 min, column 15: incubation for 50 min
Gel analysis of MS2-RNA which was isolated after incubation in serum/stabilization solution for 3 days at 40° C. The GTC content of the stabilization solution after serum addition in which the relevant RNA sample was incubated is indicated in the corresponding column. Column 1: 2.70 M GTC, column 2: 2.5 M GTC, column 3: 2.36 M GTC, column 4: 2.20 M GTC, column 5: 2.08 M GTC, column 6: 1.94 M GTC, column 7: 1.80 M GTC, column 8: 1.66 M GTC.
Gel analysis of the PCR amplificates of MS2-RNA which was isolated after 1 day and 8 days, respectively, of incubation at 40° C. in serum/stabilization solution.
Column 1: Amplificate of the RNA isolated after 1 day, column 2: amplificate of the RNA isolated after 8 days, column 3: DNA marker, column 4: MS2-RNA positive control: 0.8 μg in 10 μl RT, 1:50 diluted, 1 μl amplified.
Gel analysis of isolated MS2-RNA after 6 days (column 2-12) and 13 days (column 14-19), respectively, of incubation at room temperature in serum/stabilization solution. The pH which was obtained after mixing of serum and stabilization solution is written behind the corresponding columns.
Column 1, 13, 20: DNA marker, column 2: pH 8.0, column 3: pH 7.7, column 4: pH 7.5, column 5: pH 7.35, column 6: pH 7.18, column 7,14: pH 7.07, column 8,15: pH 6.94, column 9,16: pH 6.8, column 10,17: pH 6.72, column 11,18: pH 6.68 and column 12,19: pH 6.7. The stabilization solution of RNA in column 12, 19 had the same pH as that of the RNA in column 11, but contained 5 m GTC instead of 4 M.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2460641 *||Aug 14, 1945||Feb 1, 1949||Kleiner Joseph J||Blood collecting apparatus|
|US3847738||Nov 1, 1971||Nov 12, 1974||American Hospital Supply Corp||Blood collection and preservation unit|
|US3879295 *||Aug 17, 1973||Apr 22, 1975||Eastman Kodak Co||Vacutainer with positive separation barrier|
|US4040785||Oct 18, 1976||Aug 9, 1977||Technicon Instruments Corporation||Lysable blood preservative composition|
|US4311482||Oct 9, 1979||Jan 19, 1982||Abbott Laboratories||Method and apparatus for collecting blood samples|
|US4336880 *||Nov 24, 1980||Jun 29, 1982||Becton, Dickinson And Company||Preservation of urine specimens|
|US4342566||Feb 22, 1980||Aug 3, 1982||Scripps Clinic & Research Foundation||Solid phase anti-C3 assay for detection of immune complexes|
|US4424279 *||Aug 12, 1982||Jan 3, 1984||Quidel||Rapid plunger immunoassay method and apparatus|
|US4529614||Dec 2, 1981||Jul 16, 1985||Becton, Dickinson And Company||One step anticoagulant coating|
|US4558142 *||Sep 7, 1982||Dec 10, 1985||Hoffmann-La Roche Inc.||7-Fluoro-prostacyclin analogs|
|US4808449||Aug 25, 1986||Feb 28, 1989||Sherwood Medical Company||Method for applying a dried coating of biologicals to the interior of a container|
|US4812310||Aug 24, 1987||Mar 14, 1989||Toru Sato||Preserving solution for blood or packed blood cells and method for preserving blood or packed blood cells by using the same|
|US4843155||Nov 19, 1987||Jun 27, 1989||Piotr Chomczynski||Product and process for isolating RNA|
|US4882282 *||Jul 31, 1986||Nov 21, 1989||Immunex Corporation||DNA sequences encoding bovine interleukin-2|
|US4931543||Mar 25, 1988||Jun 5, 1990||Cetus Corporation||Process for recovering microbially produced interleukin-2|
|US4935342||Dec 1, 1986||Jun 19, 1990||Syngene, Inc.||Method of isolating and purifying nucleic acids from biological samples|
|US4938758||Nov 16, 1987||Jul 3, 1990||Al Sioufi Habib||Anti-pathogenic blood collection system and method|
|US5010183||Jul 7, 1989||Apr 23, 1991||Macfarlane Donald E||Process for purifying DNA and RNA using cationic detergents|
|US5019243 *||May 2, 1989||May 28, 1991||Mcewen James A||Apparatus for collecting blood|
|US5023323||Sep 12, 1990||Jun 11, 1991||Monsanto Company||Method of somatotropin naturation|
|US5030341 *||May 2, 1989||Jul 9, 1991||Andronic Technologies, Inc.||Apparatus for separating phases of blood|
|US5032398 *||Aug 1, 1986||Jul 16, 1991||Kaslow Harvey R||Selective modification of the catalytic subunit of pertussis toxin|
|US5046509 *||Dec 30, 1988||Sep 10, 1991||Spacelabs, Inc.||Device for the conditioning, handling and measurement of blood|
|US5073341||Aug 9, 1989||Dec 17, 1991||Biotope, Inc.||Devices for conducting specific binding assays|
|US5215892 *||Oct 22, 1990||Jun 1, 1993||Tadamitsu Kishimoto||C/EBP2 gene and recombinant C/EBP2|
|US5234809||Jul 1, 1991||Aug 10, 1993||Akzo N.V.||Process for isolating nucleic acid|
|US5300635||Feb 1, 1993||Apr 5, 1994||University Of Iowa Research Foundation||Quaternary amine surfactants and methods of using same in isolation of nucleic acids|
|US5308506 *||Dec 31, 1992||May 3, 1994||Mcewen James A||Apparatus and method for separating a sample of blood|
|US5346994||Jan 28, 1992||Sep 13, 1994||Piotr Chomczynski||Shelf-stable product and process for isolating RNA, DNA and proteins|
|US5354483 *||Oct 1, 1992||Oct 11, 1994||Andronic Technologies, Inc.||Double-ended tube for separating phases of blood|
|US5380664||Apr 17, 1990||Jan 10, 1995||Coulter Corporation||Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems|
|US5456885||Jul 12, 1993||Oct 10, 1995||Coleman; Charles M.||Fluid collection, separation and dispensing tube|
|US5459253||May 2, 1994||Oct 17, 1995||Pharmacia P-L Biochemicals Inc.||M-RNA purification|
|US5541058 *||Sep 9, 1993||Jul 30, 1996||Kreider; John W.||In vitro assay system for testing the effectiveness of anti-papilloma viral agents|
|US5545529||Mar 27, 1995||Aug 13, 1996||New York University||Assay for detecting covalent DNA-protein complexes|
|US5610287||Nov 16, 1994||Mar 11, 1997||Molecular Tool, Inc.||Method for immobilizing nucleic acid molecules|
|US5620852||Oct 31, 1994||Apr 15, 1997||Hri Research, Inc.||Nucleic acid preparation methods|
|US5637687||Aug 31, 1993||Jun 10, 1997||Wiggins; James C.||Methods and compositions for isolating nucleic acids|
|US5654179||Oct 3, 1994||Aug 5, 1997||Hri Research, Inc.||Nucleic acid preparation methods|
|US5663048 *||Oct 27, 1994||Sep 2, 1997||University Of Calgary||Y-chromosome specific polynucleotide probes for prenatal sexing|
|US5667963||Feb 21, 1996||Sep 16, 1997||Becton Dickinson And Company||Anticoagulant solution for use in blood chemistry-related techniques and apparatus|
|US5702884||Mar 12, 1996||Dec 30, 1997||Johnson & Johnson Clinical Diagnostics, Inc.||Whole blood sample preparation for polymerase chain reaction using ammonium chloride and a carboxylic acid or metal carboxylate for selective red blood cell lysis|
|US5728822||Sep 7, 1995||Mar 17, 1998||Qiagen N.V.||Quaternary amine surfactants and methods of using same in isolation of RNA|
|US5744520||Jul 19, 1996||Apr 28, 1998||Xerox Corporation||Aggregation processes|
|US5747663||Feb 3, 1995||May 5, 1998||Qiagen Gmbh||Process for the depletion or removal of endotoxins|
|US5763199 *||Sep 29, 1994||Jun 9, 1998||Mount Sinai School Of Medicine Of The City University Of New York||Platelet blockade assay|
|US5777099||Sep 4, 1996||Jul 7, 1998||Biotecx Laboratories, Inc.||RNA separation|
|US5779983||Jun 19, 1996||Jul 14, 1998||Becton, Dickinson & Company||Test tube for determining the erythrocyte sedimentation rate and a surfactant for use therein|
|US5792651||Feb 3, 1995||Aug 11, 1998||Qiagen Gmbh||Enhancement of the transfection efficiency of nucleic acids by using isopropanol in aqueous solutions|
|US5849517||Jul 16, 1996||Dec 15, 1998||Streck Laboratories, Inc.||Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same|
|US5860937 *||Apr 30, 1997||Jan 19, 1999||Becton, Dickinson & Company||Evacuated sample collection tube with aqueous additive|
|US5882318 *||Sep 28, 1993||Mar 16, 1999||Tom Robin Caine Boyde||Multichamber container for blood or other fluid samples|
|US5891736||Nov 20, 1996||Apr 6, 1999||Bayer Corporation||Reagents and methods for releasing and measuring lead ions from biological matrices|
|US5906744||Sep 9, 1997||May 25, 1999||Becton Dickinson And Company||Tube for preparing a plasma specimen for diagnostic assays and method of making thereof|
|US5932422||Nov 14, 1997||Aug 3, 1999||Millennium Pharmaceuticals, Inc.||Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase|
|US5939259||Apr 9, 1997||Aug 17, 1999||Schleicher & Schuell, Inc.||Methods and devices for collecting and storing clinical samples for genetic analysis|
|US5942191 *||Jul 14, 1997||Aug 24, 1999||Becton, Dickinson And Company||Body fluid collection vessel having reduced capacity|
|US5958677 *||Jul 28, 1997||Sep 28, 1999||The New York Blood Center, Inc.||Method for purifying viral nucleic acids|
|US5968620 *||Oct 22, 1997||Oct 19, 1999||Becton Dickinson And Company||Blood collection tube assembly|
|US5985572||Feb 23, 1998||Nov 16, 1999||Qiagen N.V.||Quaternary amine surfactant and methods of using same in isolation of RNA|
|US5989431||Jun 11, 1996||Nov 23, 1999||Progen Industries Ltd||Method and apparatus for DNA extraction|
|US5990301||Feb 3, 1995||Nov 23, 1999||Qiagen Gmbh||Process for the separation and purification of nucleic acids from biological sources|
|US5998601 *||Feb 13, 1997||Dec 7, 1999||Regents Of The University Of Minnesota||VR-2332 viral nucleotide sequence and methods of use|
|US6020186||May 16, 1995||Feb 1, 2000||Qiagen Gmbh||Device and process for isolating nucleic acids from cell suspensions|
|US6027886||Dec 20, 1996||Feb 22, 2000||Roche Diagnostics Gmbh||Method for the quantitative detection of specific nucleic acid sequences|
|US6037465||Dec 16, 1996||Mar 14, 2000||Invitek Gmbh||Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials|
|US6043032||Nov 12, 1996||Mar 28, 2000||Tosoh Corporation||Method of extracting nucleic acids and method of detecting specified nucleic acid sequences|
|US6102894 *||May 10, 1999||Aug 15, 2000||Dysarz; Edward D.||Modular retractable spring needle cannula blood collection device|
|US6111096 *||Oct 31, 1997||Aug 29, 2000||Bbi Bioseq, Inc.||Nucleic acid isolation and purification|
|US6114108||Aug 29, 1995||Sep 5, 2000||V.I. Technologies, Inc.||Methods and compositions for the selective modification of viral nucleic acids|
|US6168922||Feb 22, 1999||Jan 2, 2001||Schleicher & Schuell, Inc.||Methods and devices for collecting and storing clinical samples for genetic analysis|
|US6218531||Jun 25, 1998||Apr 17, 2001||Promega Corporation||Method of isolating RNA|
|US6231815||Nov 20, 1997||May 15, 2001||Roche Diagnostics Gmbh||Storage and transport system for sample material|
|US6245782||May 17, 1999||Jun 12, 2001||Heartdrug Research L.L.C.||Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors|
|US6258930||Mar 2, 2000||Jul 10, 2001||Qiagen Gmbh||Process and apparatus for breaking down biological material|
|US6274386||Jun 6, 1997||Aug 14, 2001||Roche Diagnostics Gmbh||Reagent preparation containing magnetic particles in tablet form|
|US6281008 *||Feb 1, 1999||Aug 28, 2001||Toyo Boseki Kabushiki Kaisha||Nucleic acid extraction apparatus|
|US6309885||Sep 24, 1999||Oct 30, 2001||Reinee Probst||Preparation of blood samples for detecting homocysteine and/or folate|
|US6329179 *||Mar 14, 1997||Dec 11, 2001||Oncomedx, Inc.||Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer|
|US6409528||Apr 27, 2000||Jun 25, 2002||Becton, Dickinson And Company||Device and method for collecting, preparation and stabilizing a sample|
|US6579672||May 23, 1997||Jun 17, 2003||Northern General Hospital||Specimen collection fluid|
|US6605444 *||Jul 22, 1997||Aug 12, 2003||Securetec Detektions-Systems Ag||Method and device for obtaining and detecting immunologically active substances from the gas phase|
|US6720417||Jan 26, 1998||Apr 13, 2004||Roche Diagnostics Gmbh||Method and device for refining nucleic acids|
|US6776959 *||Aug 12, 1999||Aug 17, 2004||Antigene Biotech Gmbh||Vessel for blood sampling|
|US6805842 *||Oct 12, 2001||Oct 19, 2004||Mds Sciex||Repuncturable self-sealing sample container with internal collapsible bag|
|US6881537 *||Aug 5, 1998||Apr 19, 2005||Biomerieux, B.V.||Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1|
|US7008765 *||Apr 9, 1998||Mar 7, 2006||The Johns Hopkins University||PCA3, PCA3 genes, and methods of use|
|US7067287||Oct 27, 1998||Jun 27, 2006||Hitachi, Ltd.||Method for recovery of nucleic acids|
|US7282371 *||Feb 15, 2001||Oct 16, 2007||Preanalytix Gmbh||Container for nucleic acid analysis|
|US20020009722||Sep 10, 1999||Jan 24, 2002||Dolores M. Berger||Composition for providing long term stability to cells for diagnostic testing|
|US20020068821||Dec 22, 1999||Jun 6, 2002||Gerard Gundling||Nucleic acid isolation method & kit|
|US20020102570||Jun 15, 2001||Aug 1, 2002||Sierra Diagnostics, Inc.||Methods and reagents for preservation of DNA in bodily fluids|
|US20020150907 *||Jul 18, 2001||Oct 17, 2002||Fomovskaia Galina N.||Methods for the isolation of nucleic acids and for quantitative DNA extraction and detection for leukocyte evaluation in blood products|
|EP0389063A2||Mar 22, 1990||Sep 26, 1990||Akzo Nobel N.V.||Process for isolating nucleic acid|
|EP0554034A1||Jan 25, 1993||Aug 4, 1993||Piotr Chomczynski||Shelf-stable product and process for isolating RNA, DNA and proteins|
|EP0818542A1||Jul 1, 1997||Jan 14, 1998||Labordiagnostika Gesellschaft mbH||Method for the stabilisation of nucleic acids prior to their isolation from blood samples|
|WO1994018156A1||Jan 12, 1994||Aug 18, 1994||Univ Iowa Res Found||Quartenary amine surfactants and methods of using same in isolation of rna|
|WO1997005248A2||Jul 18, 1996||Feb 13, 1997||Chomczynski Piotr||Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins|
|WO1998032877A1||Jan 26, 1998||Jul 30, 1998||Boehringer Mannheim Gmbh||Method and device for refining nucleic acids|
|1||"BD Vacutainer plus EDTA Tubes," 2000, BD Vacutainer Systems, p. 1.|
|2||A Newsletter from Becton, Dickinson Vacutainer Systems, Lab Notes, vol. 8, No. 3, 1998, pp. 1-8.|
|3||Adeline R. Whitney, Maximilian Diehn, Stephen J. Popper, Ash A. Alizadeh, Jennifer C. Boldrick, David A. Relman and Patrick O. Brown, "Individuality and variation in gene expression patterns in human blood"; PNAS, vol. 100, No. 4, Feb. 18, 2003, pp. 1896-1901.|
|4||Andreas Pahl and Kay Brune, "Gene expression changes in blood after phlebotomy: implications for gene expression profiling"; Blood, Aug. 1, 2002-vol. 100, No. 3, pp. 1094-1095.|
|5||Andreas Pahl and Kay Brune, "Stabilization of Gene Expression Profiles in Blood after Phlebotomy"; Clinical Chemistry 48, No. 12, 2002, pp. 2251-2253.|
|6||Andreas Pahl and Kay Brune, "Gene expression changes in blood after phlebotomy: implications for gene expression profiling"; Blood, Aug. 1, 2002—vol. 100, No. 3, pp. 1094-1095.|
|7||*||Brossart et al., Cancer Research 55 : 4065-4068 (1995).|
|8||*||Brossart et al., J. of Invest. Derm. 101:887-889 (1993).|
|9||*||Chomczynski et al., Analytical Biochemisty 162 : 156-159 (1987).|
|10||Christopher Hartel, Gregor Bein, Michael Muller-Steinhardt, and Harald Kluter "Ex vivo induction of cytokine mRNA expression in human blood samples"; Journal of Immunological Methods, 249, (2001) pp. 63-71.|
|11||*||Curry et al., J. Clin. Oncol. 16 : 1760-1769 (1998).|
|12||Dawes, et al., Thrombosis Research, 12(5): 851-61 (1978).|
|13||*||De Vires et al., Br J Cancer 80 : 883-8991 (1999).|
|14||*||Farthmann et al., J. of Invest. Derm. 110:263-268 (1998).|
|15||*||Foss et al., Br J Cancer 72 :155-159 (1995).|
|16||*||Guanidinium Thiocyanate, Materials Safety Data Sheet, pp. 1-5.|
|17||Guide Mol. Cloning Tech. (1987), Methods Enzymd., vol. 152, pp. 219-227.|
|18||Holodniy, et al., J. Clin. Microbiology, 29:676-679 (1991).|
|19||*||Hoon et al., J. Clin Oncol 13 : 2109-2116 (1995).|
|20||*||Keilholz et al., Euro J. Cancer 34 : 750-753 (1998).|
|21||*||Keilholz et al., Melanoma Research 7 : S133-S141 (1997).|
|22||Kuhne, T. et al., "Flow Cytometric Evaluation of Platelet Activation in Blood Collected into EDTA vs. Diatube-H, A Sodium Citrate Solution Supplemented with Theophyline, Adenosine and Dipyridamole." American Journal of Hematology, New York, New York; US., vol. 50, No. 1, 1995, pp. 40-45.|
|23||*||Kunter et al., J Nat Cancer Inst. 88 : 590-594 (1996).|
|24||Lahiri, D. K. et al; "DNA Isolation by a Rapid Method from Human Blood Samples; Effect of MGCL2, EDTA, Storage Time, and Temperature on DNA Yield and Quality," Biochemical Genetics, Plenum Press Co., London, GB, vol. 31, No. 7/8, Aug. 1993 (1993/08), pp. 321-323.|
|25||*||Lozano et al. A Simple nucleic acid amplification assay for the rapid detection of Junin virus in whole blood samples. Virus Research 27 : 37-53 (1993).|
|26||*||Lozano et al., Virus Research 27 : 37-53 (1993).|
|27||Lozano, M.E. et al. (1993) "A simple nucleic acid amplification assay for the rapid detection of Junin virus in whole blood samples", Virus Research, vol. 27, pp. 37-53, (XP002900733).|
|28||Lozano, M.E., et al.(1993) "A Simple nucleic acid amplification assay for the rapid detection of Junin virus in whole blood samples", Virus Research, vol. 27, pp. 37-53, (XP002900733).|
|29||Ludlam et al., Thrombosis Research, 6(6): 543-48 (1975).|
|30||Lynne Rainen, Uwe Oelmueller, Stewart Jurgensen, Ralf Wyrich, Cynthia Ballas, Jim Schram, Chris Herdman, Danute Bankaitis-Davis, Nancy Nicholls, David Trollinger and Victor Tryon, "Stabilization of mRNA Expression in Whole Blood Samples"; Clinical Chemistry 48:11, pp. 1883-1890.|
|31||Mac Donald, R.J. et al. (1988) "Isolation of RNA using guanidinium salts", Chemical Abstracts, vol. 108, p. 324. (XP002900734).|
|32||Mac Donald, R.J., et al. (1988) "Isolation of RNA using guanidinium salts", Chemical Abstracts, vol. 108, p. 324. (XP002900734).|
|33||*||MacDonald et al. Isolation of RNA using Guanidinium Salts. Methods in Enzymology 152 : 219-227 (1987).|
|34||Mc Muller, K Merx, Z Weiber, X Kreil, T Lahaye, R Hehlmann and A Hochhaus, "Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization"; Leukemia (2002) 16, pages 2395-2399.|
|35||*||Mellado et al., J. Clin Oncol 14 : 2091-2097 (1996).|
|36||Oelrichs, Robert B et al; The Explosive Human Immunodeficiency Virus Type 1 Epidemic among injecting Drug Users of Kathmandu, Nepal, is Caused by Subtype C Virus of Restricted Genetic ; Journal of Virology; vol. 74, No. 3, Feb. 2000, pp. 1149-1157.|
|37||Pfiefer, P.H. et al., "Possible mechanism for invitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation," Clinical Chemistry, American Association for Clinical Chemistry. Winson, U.S., vol. 45, No. 8, Aug. 1999 (1999-08), pp. 1190-1199.|
|38||Raymond J. MacDonald, Galvin H. Swift, Alan E. Przybyla, and John M. Chirgwin, "Isolation of RNA Using Guanidinium Salts"; Methods in Enzymology, vol. 152 , (1987), pp. 219-227.|
|39||Schmidt, Warren N., et al.; "Direct Detection of Hepatitis C Virus (HCV) RNA from Whole Blood and Comparison with HCV RNA in Plasma and Peripheral Blood Mononuclear Cells"; Journal of Virology; vol. 47, No. 2; 1995; pp. 153-160.|
|40||*||Smith et al., Lancet 338 : 1227-1229 (1991).|
|41||*||Tobal et al. Invest Ophthamol. Vis Sci 34 : 2622-2625 (1993).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US9078426||Jul 30, 2008||Jul 14, 2015||Biomatrica, Inc.||Integration of sample storage and sample management for life science|
|US20120064525 *||Nov 18, 2011||Mar 15, 2012||Olympus Corporation||Method for collection of nucleic acid derived from mammalian cell, method for analysis of nucleic acid, and kit for collection of feces|
|U.S. Classification||435/6.1, 600/577, 536/25.4, 435/4, 436/176, 436/174, 435/283.1, 435/287.2, 600/573, 435/2, 422/50|
|International Classification||C12N15/10, C12Q1/68, C12M3/00, C12M1/34, C07H21/00, G01N1/00, G01N21/00, B01L3/00, A01N1/02, G01N33/48, A61B5/00, C12M1/00|
|Cooperative Classification||Y10T436/2525, Y10T436/25, A61B5/1438, C12Q1/6806, C12N15/1003|
|European Classification||C12Q1/68A4, C12N15/10A|
|Apr 9, 2012||AS||Assignment|
Owner name: GREINER BIO-ONE GMBH, AUSTRIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HELFTENBEIN, ELKE;REEL/FRAME:028015/0165
Effective date: 20010504
Owner name: ANTIGENE BIOTECH GMBH, GERMANY
Free format text: CHANGE OF NAME;ASSIGNOR:ANTIGEN PRODUKTIONS GMBH;REEL/FRAME:028018/0146
Effective date: 20010824
Owner name: PREANALYTIX GMBH, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANTIGENE BIOTECH GMBH;REEL/FRAME:028015/0269
Effective date: 20050214
Owner name: ANTIGENE BIOTECH GMBH, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREINER BIO-ONE GMBH;REEL/FRAME:028015/0251
Effective date: 20031124
Owner name: ANTIGEN PRODUKTIONS GMBH, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HELFTENBEIN, ELKE;REEL/FRAME:028015/0165
Effective date: 20010504